In vitro, JNJ-5322 induced potent and dose-dependent cytotoxicity with concomitant T-cell activation only in MM cell lines that expressed one or both target proteins (BCMA, GPRC5D). The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.